Macrocytic anemia and thrombocytopenia induced by orlistat

International Journal of Endocrinology and Metabolism

Volumn 11, Issue 4, 2013, Pages

  Palacios Martinez, David ^a   Garcia Alvarez, Juan Carlos ^b   Montero Santamaria, Nieves ^a   Villar Ruiz, Olga Patricia ^c   Ruiz Garcia, Antonio ^d   Diaz Alonso, Raquel Asuncion ^a  

^a Madrid Health Service   (Spain)

^b SERMAS Madrid Health Service   (Spain)

^c HOSPITAL UNIVERSITARIO 12 DE OCTUBRE   (Spain)

^d Primary Health Care   (Spain)

Author keywords

Anti obesity agents; Obesity; Obesity, morbid; Thrombocytopenia

Indexed keywords

DOXYCYCLINE; TETRAHYDROLIPSTATIN;

ADULT; ARTICLE; CASE REPORT; DIET THERAPY; DRUG WITHDRAWAL; FATIGUE; FEMALE; HIDRADENITIS; HUMAN; KINESIOTHERAPY; MACROCYTIC ANEMIA; MORBID OBESITY; SKIN BRUISING; SPLENOMEGALY; THROMBOCYTOPENIA; WEIGHT REDUCTION;

EID: 84890075093     PISSN: 1726913X     EISSN: 17269148     Source Type: Journal    
DOI: 10.5812/ijem.6721     Document Type: Article

References (20)

1. Dyson PA. The therapeutics of lifestyle management on obesity. Diabetes Obes Metab. 2010;12(11):941-6.
2. Kang JG, Park CY. Anti-Obesity Drugs: A Review about Their Effects and Safety. Diabetes Metab J. 2012;36(1):13-25.
3. Carrasco NF, Manrique M, de la Maza MP, Moreno M, Albala C, Garcia J, et al. [Statement about the medical and surgical treatment of overweight and obesity]. Rev Med Chil. 2009;137(7):972-81.
4. Ballinger Anne, Peikin Steven R. Orlistat: its current status as an anti-obesity drug. Eur J Pharmacol. 2002;440(2-3):109-117.
5. Bloch Katia Vergetti, Salles Gil Fernando, Muxfeldt Elizabeth Silaid, da Rocha Nogueira Armando. Orlistat in hypertensive over-weight/obese patients. J Hypertens. 2003;21(11):2159-2165.
6. MacWalter RS, Fraser HW, Armstrong KM. Orlistat enhances warfarin effect. Ann Pharmacother. 2003;37(4):510-2.
7. Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Orlistat-associated adverse effects and drug interactions: a critical review. Drug Saf. 2008;31(1):53-65.
8. Ahmad FA, Mahmud S. Acute pancreatitis following orlistat therapy: report of two cases. JOP. 2010;11(1):61-3.
9. García Aguilera Xavier, Teruel Sánchez-Vegazo Carlos, Crespo Pérez Laura, Moreira Vicente Víctor. Pancreatitis aguda inducida por orlistat. Medicina Clínica. 2008;130(14):557.
10. Karamadoukis L, Shivashankar GH, Ludeman L, Williams AJ. An unusual complication of treatment with orlistat. Clin Nephrol. 2009;71(4):430-2.
11. Kim DH, Lee EH, Hwang JC, Jeung JH, Kim do H, Cheong JY, et al. [A case of acute cholestatic hepatitis associated with Orlistat]. Taehan Kan Hakhoe Chi. 2002;8(3):317-20.
12. Lau G, Chan CL. Massive hepatocellular [correction of hepa-tocullular] necrosis: was it caused by Orlistat? Med Sci Law. 2002;42(4):309-12.
13. Ringman JM, Mozaffar T. Myopathy associated with chronic orlistat consumption: a case report. Neuromuscul Disord. 2008;18(5):410-2.
14. Perdue BE, Standiford HC, Yu VL, Merigan, TC, Barriere, SL. Tetracyclines. In: Antimicrobial Therapy and Vaccines. Perdue BE, Standiford HC, Yu VL, Merigan, TC, Barriere, SL, editors: Lippincott Williams&Wilkins; 1998.
15. Hoffbrand V, Provan D. ABC of clinical haematology. Macrocytic anaemias. BMJ. 1997;314(7078):430-3.
16. Savage David, Lindenbaum John. Anemia in Alcoholics. Medicine. 1986;65(5):322-338.
17. Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med. 2007;357(6):580-7.
18. Christie DJ, Mullen PC, Aster RH. Fab-mediated binding of drug-dependent antibodies to platelets in quinidine- and quinine-induced thrombocytopenia. J Clin Invest. 1985;75(1):310-4.
19. Greinacher A, Fuerll B, Zinke H, Mullejans B, Kruger W, Michetti N, et al. Megakaryocyte impairment by eptifibatide-induced antibodies causes prolonged thrombocytopenia. Blood. 2009;114(6):1250-3.
20. Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts EA, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30(2):239-45.